Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I plus N).

被引：0
|
作者：
Desai, Kunal
Rybicki, Lisa A.
Nizam, Amanda
Wood, Laura S.
Allman, Kimberly D.
Martin, Allison
Calabrese, Cassandra
Gilligan, Timothy D.
Gupta, Shilpa
Ornstein, Moshe Chaim
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17094
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study
    Vitale, Maria Giuseppa
    Pipitone, Stefania
    Venturelli, Marta
    Baldessari, Cinzia
    Porta, Camillo
    Iannuzzi, Federica
    Basso, Umberto
    Scagliarini, Sarah
    Zucali, Paolo Andrea
    Galli, Luca
    Rossetti, Sabrina
    Caserta, Claudia
    Bracarda, Sergio
    Iacovelli, Roberto
    Masini, Cristina
    Cortellini, Alessio
    Di Girolamo, Stefania
    Buti, Sebastiano
    Fornarini, Giuseppe
    Carrozza, Francesco
    Santoni, Matteo
    Caputo, Francesco
    Giaquinta, Stefania
    Balduzzi, Sara
    D'Amico, Roberto
    Vitale, Giovanna
    Mighali, Pasquale
    Sabbatini, Roberto
    CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : 477 - 488
  • [22] Correlation between immune-related adverse events and prognosis in renal cell carcinoma patients treated with nivolumab
    Kato, Taigo
    Nagahara, Akira
    Kawamura, Norihiko
    Nakata, Wataru
    Soda, Tetsuji
    Matsuzaki, Kyosuke
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Imamura, Ryoichi
    Nishimura, Kensaku
    Takada, Shingo
    Tsujihata, Masao
    Yamaguchi, Seiji
    Takao, Tetsuya
    Nishimura, Kazuo
    Uemura, Motohide
    Nonomura, Norio
    ANNALS OF ONCOLOGY, 2021, 32 : S314 - S314
  • [23] Editorial Comment to Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study
    Tamada, Satoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (12) : 1100 - 1101
  • [24] Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States
    Doshi, Gurjyot K.
    Osterland, Andrew J.
    Shi, Ping
    Yim, Annette
    Del Tejo, Viviana
    Guttenplan, Sarah B.
    Eiffert, Samantha
    Yin, Xin
    Rosenblatt, Lisa
    Conkling, Paul R.
    JCO CLINICAL CANCER INFORMATICS, 2024, 8
  • [25] Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renalcell carcinoma (mRCC) treated with ipilimumab/nivolumab (I plus N).
    Zhang, Tian
    Wu, Yuan
    Agarwal, Anika
    Starr, Mark D.
    Reyes-Martinez, Marco
    Anand, Monika
    Runyambo, Daniella
    Harrison, Michael Roger
    Armstrong, Andrew J.
    George, Daniel J.
    Nixon, Andrew B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [26] Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).
    Ali, Sana
    Leong, Sally
    Meza, Luis A.
    Dizman, Nazli
    Zengin, Zeynep Busra
    Kim, Tane
    Pak, Youngju
    Onyshchenko, Mykola
    Pal, Sumanta K.
    Chehrazi-Raffle, Alex
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Impact of treatment line on outcomes with salvage ipilimumab plus nivolumab in metastatic renal cell carcinoma (mRCC).
    Kotecha, Ritesh
    Lee, Chung-Han
    Knezevic, Andrea
    Shah, Neil J.
    Carlo, Maria Isabel
    Feldman, Darren R.
    Patil, Sujata
    Motzer, Robert J.
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma A Cost-effectiveness Analysis
    Wan, XiaoMin
    Zhang, YuCong
    Tan, ChongQing
    Zeng, XiaoHui
    Peng, LiuBao
    JAMA ONCOLOGY, 2019, 5 (04) : 491 - 496
  • [29] Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
    Kobayashi, Mizuki
    Numakura, Kazuyuki
    Hatakeyama, Shingo
    Muto, Yumina
    Sekine, Yuya
    Sasagawa, Hajime
    Kashima, Soki
    Yamamoto, Ryohei
    Koizumi, Atsushi
    Nara, Taketoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    GENES, 2022, 13 (07)
  • [30] Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma
    Tasaki, Yoshihiko
    Hamamoto, Shuzo
    Sugiyama, Yosuke
    Tomiyama, Nami
    Naiki, Taku
    Etani, Toshiki
    Taguchi, Kazumi
    Matsuyama, Nayuka
    Sue, Yasuhito
    Mimura, Yoshihisa
    Kubota, Hiroki
    Noda, Yusuke
    Aoki, Maria
    Moritoki, Yoshinobu
    Nozaki, Satoshi
    Kurokawa, Satoshi
    Okada, Atsushi
    Kawai, Noriyasu
    Yasui, Takahiro
    Kimura, Kazunori
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (10) : 866 - 874
12345